

**DOCKET NO: ISIS0064-100 (RTS-0175)****PATENT****In the Claims:**

Please amend claim 1 as follows.

1. (currently amended) A ~~compound~~ An oligomeric compound 8 to 50 nucleobases in length targeted to a nucleic acid molecule encoding human dual specific phosphatase 5 (SEQ ID NO:10), wherein said compound inhibits the expression of human dual specific phosphatase 5 by at least 40%.
2. (Original) The compound of claim 1 which is an antisense oligonucleotide.
3. (Canceled).
4. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified internucleoside linkage.
5. (Original) The compound of claim 4 wherein the modified internucleoside linkage is a phosphorothioate linkage.
6. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified sugar moiety.
7. (Original) The compound of claim 6 wherein the modified sugar moiety is a 2'-O-methoxyethyl sugar moiety.
8. (Original) The compound of claim 2 wherein the antisense oligonucleotide comprises at least one modified nucleobase.
9. (Original) The compound of claim 8 wherein the modified nucleobase is a 5-methylcytosine.

DOCKET NO: ISIS0064-100 (RTS-0175)

PATENT

10. (Original) The compound of claim 2 wherein the antisense oligonucleotide is a chimeric oligonucleotide.
11. (Canceled).
12. (Original) A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier or diluent.
13. (Original) The composition of claim 12 further comprising a colloidal dispersion system.
14. (Original) The composition of claim 12 wherein the compound is an antisense oligonucleotide.
15. (Previously presented) A method of inhibiting the expression of dual specific phosphatase 5 in cells or tissues comprising contacting said cells or tissues *in vitro* with the compound of claim 1 so that expression of dual specific phosphatase 5 is inhibited.
- 16-20 (Canceled).